Select your region

To ensure that the content you receive is tailored to your region, please select your location from the available options. By doing so, we will be able to provide you with information pertaining to products and services that are specific to your region. This will enable us to better meet your needs and ensure that you receive the best experience possible.

Ankyras
Clinical Research & Publications

ANKYRAS
Neurovascular
Ankyras simulation for flow diversion of intracranial aneurysms: a standardized workflow integrated clinical validation study

Background: Accurate flow diverter (FD) sizing is critical for successful intracranial aneurysm (IA) treatment. We evaluated the predictive performance of the Ankyras FD simulation platform within a standardized simulation based clinical workflow using three-dimensional (3D) DynaCTA centerline analysis as an advanced validation reference standard. Methods: A retrospective analysis of a prospectively maintained institutional database of Ankyras guided IA treatments between April 2024 and October 2025 was performed. 3D rotational angiography data generated Ankyras simulations for treatment planning, device selection, and intraoperative guidance. Simulated length (SL) and proximal landing zone (PLZ) were compared with post-deployment length (DL) from DynaCTA centerline measurements (3D Slicer). Accuracy was assessed using correlation coefficients, mean absolute error (MAE), and Bland-Altman analysis. Results: 54 consecutive patients (48 women, mean age 54.2 years) with 63 IAs underwent 57 pipeline embolization device (PED) treatments. All achieved procedural success without intraoperative complications; two required adjunctive stent placement for malapposition. Mean SL was 21.44±3.53 mm and DL was 21.49±3.52 mm (n=46), with a strong SL-DL correlation (r=0.91), minimal bias (-0.05 mm), and 1.24 mm MAE. PLZ demonstrated a strong correlation (r=0.94), low bias (0.14 mm), and minimal MAE (1.34 mm) between Ankyras and the deployed values (n=45). Bland-Altman analysis showed narrow agreement limits without evidence of proportional error. Conclusions: Using a robust 3D DynaCTA centerline based validation, Ankyras demonstrated high accuracy for PED deployment length and landing zone prediction within a standardized clinical treatment workflow of pre-procedural planning, intraoperative guidance, and post-deployment assessment.

Alan R Rheaume, Christine Denice, Seyed Morsal Mosallami Aghili, Michael Jean, Carla Guerrero, Lukasz Chojnowski, Daniel Kim, Tasnim Tanim, Eric Birmingham, Ryan J Fernandez, Tiffany Ang, Sanjana Iyer, Shoaib Syed, David Fiorella, Chander Sausdivan
Published:
August 30, 2026
View Publication
Mentice: Link to similar products  within the neuroradiologists
ANKYRAS
Neurovascular
Virtual simulation accurately predicts in vivo flow diverter length for intracranial aneurysm treatment: a multicenter validation study

Background: Accurate device sizing is crucial for successful flow diverter (FD) therapy in intracranial aneurysms. This study assesses the accuracy and clinical utility of the Ankyras virtual simulation software (Mentice AB, Gothenburg, Sweden) in predicting FD length across multiple device types and manufacturers. Methods: We retrospectively analyzed 193 FDs (7 device types) deployed in 180 patients with 230 intracranial aneurysms. Simulation-based prediction of effective lengths (simulated length (SL)) and nominal manufacturer specifications (labeled length) were compared with measured in vivo lengths (measured length (ML)). Performance was evaluated using simulation accuracy (SA), absolute error (AE), relative error (RE), length ratio, and correlation analysis. Results: Virtual simulation demonstrated good clinical usability, achieving a mean absolute deviation of only -1.38 mm at the proximal landing zone compared with ML. Simulation-based predictions showed significantly superior accuracy compared with nominal manufacturer specifications (SA 89.6±11.3% vs 81.8±13.7%, P<0.001), with mean AE reduced by 58% (-1.38 mm vs -3.34 mm) and mean RE by 42% (10.5% vs 18.2%). Strong correlations between SL and ML (r=0.900) validated predictive reliability across all tested device types. Centerline correction technology further enhanced parameters such as SA to 94.8±9.5%. Conclusion: Virtual simulation-based prediction of effective FD length using the Ankyras software showed reliable and clinically meaningful results, enabling accurate estimations of the proximal landing zone and overall length. Ankyras, along with comparable simulation platforms, may provide considerable potential to facilitate FD selection and implementation, especially in anatomically complex cases.

komma Maximilian Rothe, Thomas Liebig, Martin Renz, Maria Teresa Berndt-Mück, Dennis M Hedderich, Dominik Sepp, Bernhard Meyer, Chiara Negwer, Jannis Bodden, Florian Schoeberl, Johannes Rueckel, Jan S Kirschke, Silke Wunderlich, Tobias Boeckh-Behrens, Christian Maegerlein
Published:
January 30, 2026
View Publication
Mentice: Link to similar products  within the neuroradiologists
ANKYRAS
Software-based simulation for pipeline vantage flow diverter preprocedural assessment: Method and validation study

Flow diverters (FDs) have revolutionized intracranial aneurysm (IA) treatment. Proper FD sizing is crucial for aneurysm occlusion and complication prevention. Ankyras (Mentice, Gothenburg, Sweden) is a device-specific sizing software. We evaluated Ankyras’ performance in predicting the final deployment of the Pipeline™ Vantage Embolization Device with Shield Technology™ (PVST) (Medtronic Neurovascular, Irvine, California, USA).

João Victor Sanders, Marion Oliver, Laura Obradó, Nieves Montes, Krishna Joshi and Demetrius Lopes
Published:
August 22, 2025
View Publication
Mentice: Link to similar products  within the neuroradiologists
ANKYRAS
Neurovascular
Assessing flow diverter porosity: a comparative analysis of quantification techniques based on imaging and simulation

Flow diverter porosity directly influences the blood flow reduction at the aneurysm neck level and the anatomical result of the treatment. In this research, we present and compare three methodologies to determine the local porosity of deployed flow diverters.

https://doi.org/10.1080/17434440.2024.2437519
Published:
December 7, 2024
View Publication
Mentice: Link to similar products  within the neuroradiologists
ANKYRAS
Neurovascular
Modification of Woven Endo-Bridge After Intracranial Aneurysm Treatment: A Methodology for Three-Dimensional Analysis of Shape and Relative Position Changes

Purpose: During follow-up of patients treated with WEB devices, shape changes have been observed. The quantitative three-dimensional measurement of the WEB shape modification (WSM) would offer useful information to be studied in association with the anatomical results and try to better understand mechanisms implicated in this modification phenomenon.

Ann Biomed Eng 52, 1403–1414 (2024). https://doi.org/10.1007/s10439-024-03465-5
Published:
February 24, 2024
View Publication
Mentice: Link to similar products  within the neuroradiologists
ANKYRAS
Neurovascular
Early Results in Flow Diverter Sizing by Computational Simulation: Quantification of Size Change and Simulation Error Assessment

Sizing of flow diverters (FDs) stent in the treatment of intracranial aneurysms is a challenging task due to the change of stent length after implantation

Oper Neurosurg (Hagerstown) . 2018 Nov 1;15(5):557-566.
ANKYRAS
Neurovascular
Cerebral Aneurysm Occlusion at 12-Month Follow-Up After Flow-Diverter Treatment: Statistical Modeling for V&V With Real-World Data

Flow-Diverter (FD) porosity has been pointed as a critical factor in the occlusion of cerebral aneurysms after treatment. Objective: Verification and Validation of computational models in terms of predictive capacity, relating FD porosity and occlusion after cerebral aneurysms treatment.

Front Med Technol . 2021 Sep 17;3:705003

Learn more or request a product demonstration

We are here to guide and help you find the solution that is the best fit for your unique needs. Fill in the form to connect with us and a suitable solution expert will get back to you as soon as possible

Rambla Catalunya 53, 4-H, 08007, Barcelona, Spain.

+34 933 28 39 64

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Disclaimer & Regulatory Information

Ankyras is manufactured by Mentice Spain S.L.
ANKYRAS is intended to be used by physicians trained in medical procedures involving percutaneous and intravascular interventions.
Ankyras is 510(k) cleared by FDA.

Mentice Spain SL: Mentice Spain SL has obtained the ISO 13485 certification with number MD 784027
Ankyras certifications: The Ankyras product complies with the Medical Device Regulation (EU CE Mark, MDR 784032) and the UK Conformity Assessed (UKCA 784033)